New England Journal of Medicine
-
November 3, 2016
Study details rare heart risk of certain cancer therapies
-
October 27, 2016
Emerging field of cardio-oncology seeks better tools
Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism. -
September 30, 2015
Reduced-nicotine cigarettes decreased dependence and frequency of smoking: NEJM study
Reduced-nicotine cigarettes were beneficial in reducing nicotine exposure and dependence, and also the number of cigarettes smoked per day, when compared with standard-nicotine cigarettes in a six-week study published in the New England Journal of Medicine. -
August 20, 2015
New type of trial shows promise for several cancers
Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation. -
August 6, 2015
New targeted therapy shows promise for rare joint tumor
Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities. -
February 26, 2015
Respiratory viruses are main childhood pneumonia culprit: Study
Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine. -
January 15, 2015
New drugs approved to fight idiopathic pulmonary fibrosis
The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).